Seoul National University Bundang Hospital

Seoul National University Bundang Hospital in Seoul, South Korea has been recently validated for Stage 6 of the classic HIMSS Analytics Maturity Assessment Model . AMAM measures an organisation's capabilities and advances in healthcare analytics. A new, modernised version of this model – dubbed AMAM24 – was launched at the recently concluded HIMSS24 APAC conference. WHY IT MATTERS SNUBH credits its latest achievement to its prior experience getting validated four times for Stage 7 of the HIMSS Electronic Medical Record Adoption Model . Its Data Convergence Team under the Office of Hospital Information led this process and ensured close collaboration between the medical informatics and hospital operation teams. One of the highlights of the validation is the CDW 3.0, an upgraded version of a clinical data warehouse that the hospital had used for a decade. SNUBH embarked on this upgrade two years ago to create "an advanced, open-source data warehouse equipped with machine learning capabilities." Following the launch of the CDW 3.0 in October last year, SNUBH staff reported an increase in data retrieval and analysis speeds with the use of the system. The CDW now has a user-friendly interface that allows step-by-step patient cohort definition. It also streamlines data visualisation; enhances data security with masking and anonymisation modules; standardises unstructured data and aligns with international standard codes; and provides a single source of learning resources, including pre-defined datasets for ML/AI research. In their validation, HIMSS noted that the consolidated CDW was "accessible, convenient, and user-friendly." "This makes it a tremendously powerful tool for executives and clinicians to view, understand and analyse data, and generate insights to improve clinical care and organisational performance," Andrew Pearce, HIMSS VP Analytics and Global Advisory Lead, commented. Validators also commended SNUBH for tracking and reporting over 200 indicators via several dashboards. An example of this is the dashboard for the Rapid Response System (RRS). The hospital first set up the RRS in 2012 to resolve usual delays in responding to patient deterioration. Now in its second phase of implementation, the RRS operates round-the-clock with 15 nurses. The hospital observed a "significant decrease" in cardiopulmonary resuscitation events in the general wards over a decade since the system was first activated. Another notable improvement is the RRS dashboard facilitating a prompt transfer of patients to the ICU. In addition, SNUBH demonstrated during its AMAM validation the implementation of an AI-based ECG interpretation tool on its HIS, which is now used to generate quantitative risk assessments of cardiac events and assist with diagnosing arrhythmias and other related emergency conditions. The project aims to address delays in detecting cardiac issues and enable the creation of personalised treatment plans. Based on a test pilot prior to its initial integration in April this year, the AI tool showed proficiency in rhythm analysis and classification of 10 identified digital biomarkers. Following clinical integration, SNUBH clinicians highlighted the tool's ability to diagnose severe hyperkalemia early. Evaluation studies are ongoing to further prove its effectiveness. After this AMAM validation, SNUBH is moving on with plans to strengthen its enterprise data warehouse and improve its operational data analysis capabilities, focusing on post-monitoring systems to incorporate the analytical life cycle – which is now part of the modernised AMAM. THE LARGER TREND Fellow Korean hospital, Samsung Medical Center , became the first hospital in Asia-Pacific to get validated for Stage 7 of the HIMSS AMAM in May. It was also the first in the region to achieve Stage 6 last year. Outside South Korea, China Medical University Hospital of Taiwan is also currently validated for Stage 6 HIMSS AMAM. Meanwhile, SNUBH underwent its fourth validation for the HIMSS EMRAM late last year. The hospital was the first outside the United States to be validated for Stage 7 of this model in 2010. ON THE RECORD "SNUBH has consistently built its data analysis capabilities, which have been progressively validated through our previous four EMRAM certifications. I am delighted that we have once again affirmed our data analysis competency through this AMAM Stage 6 certification. This achievement not only recognises our current capabilities but also sets the stage for our continued advancement in leveraging data for improved healthcare delivery and operational excellence," Dr Junghan Song, president and CEO of SNUBH, said in a statement. "We specifically chose HIMSS AMAM validation to strengthen our data-driven decision-making abilities and evaluate the current state of our data-related platforms. SNUBH has evolved alongside HIMSS certifications, and we are committed to continuing this journey into the future. As highlighted at HIMSS APAC 2024, the newly modernised AMAM validation is well-designed. Through this framework, we once again aim to drive innovation in data-driven decision-making across both our clinical and operational domains," Dr Seyoung Jung, CIO of SNUBH, also commented.

HIMSS today announced an update to its Adoption Model for Analytics Maturity at the HIMSS24 Asia-Pacific conference in Seoul. The earlier version of AMAM will now be referred to as AMAM Classic and the modernised version will be referred to as AMAM24. WHY IT MATTERS The new AMAM maturity framework centres on five key imperatives for healthcare organisations: Governance; Analytics life cycle; Data and infrastructure; Personalised analytics; and Analytics impact and outcomes. HIMSS redesigned the AMAM to enable the successful adoption of advanced analytics, and AI in particular, for health organisations to achieve priority outcomes. It begins with the foundational requirements of data, digital infrastructure, and governance. Like the other HIMSS maturity models, AMAM24 is structured around a ladder of eight maturity stages - from zero to seven - to help healthcare organisations optimise their healthcare analytics capabilities, offering an evidence-based framework for improving data governance, predictive analytics, and AI usage. THE LARGER TREND Globally, 26 organisations achieved Stage 6 and 13 have achieved Stage 7 for the AMAM. In APAC, two organisations ( China Medical University Hospital , and Seoul National University Bundang Hospital) have reached AMAM Stage 6. South Korea's Samsung Medical Centre is the only organisation in APAC to have achieved Stage 7 . ON THE RECORD "AMAM24 does not prescribe what policy framework should be used in an organisation; however, it does require evidence of analytics strategy and governance policies which support and enable safety and quality of care," said Widi Salim, Senior Digital Health Advisor, HIMSS. "AMAM24 expands its earlier focus on data and IT to also now include prescriptive analytics, and data driven decision making."

TUESDAY, Sept. 3, 2024 -- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a study published online Aug. 28 in The BMJ . Anna Shin, from Seoul National University Bundang Hospital in South Korea, and colleagues compared the risk for dementia associated with SGLT-2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors in adults (aged 40 to 69 years) with type 2 diabetes. The analysis included 110,885 propensity-matched pairs followed for a mean of 670 days. The researchers found that the incidence rate for dementia was 0.22 per 100 person-years in initiators of SGLT-2 inhibitors and 0.35 per 100 person-years in initiators of DPP-4 inhibitors (hazard ratios: 0.65 for dementia, 0.54 for dementia requiring drugs, 0.61 for Alzheimer disease, and 0.48 for vascular dementia). Findings persisted regardless of dementia type and across subgroups categorized by age, sex, concomitant use of metformin, and baseline cardiovascular risk. When adjusting for residual confounding (measured by cataract surgery), the risk for dementia remained lower (hazard ratio, 0.70). The association was stronger for treatment of more than two years (hazard ratio, 0.57). "Highly consistent results over a range of secondary and sensitivity analyses supported the robustness of our study findings," the authors write. Abstract/Full Text Editorial Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.